Companies › Halozyme Therapeutics
1 active drug program in 5 registered trials: 4 Phase 2, 1 Phase 3; Neurology, Metabolic and endocrine, Oncology; next expected readout Mar 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Testosterone Enanthate Androgen Receptor agonist | AR | Phase 3 | Hypogonadism, Male; Spinal Cord Injury; Prostate Cancer; Castration Resistant Metastatic Prostate Cancer … | Mar 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04460872 | Testosterone Enanthate | Phase 2 | Spinal Cord Injury | Neurology | Jan 2026 |
| NCT06594926 | Testosterone Enanthate | Phase 2 | Prostate Cancer | Oncology | Dec 2026 |
| NCT04363164 | Testosterone Enanthate | Phase 2 | Castration Resistant Metastatic Prostate Cancer | Oncology | Jul 2027 |
| NCT03522064 | Testosterone Enanthate | Phase 2 | Castration-resistant Prostate Cancer | Oncology | Dec 2027 |
| NCT06689085 | Testosterone Enanthate | Phase 3 | Hypogonadism, Male | Metabolic and endocrine | Mar 2028 |
Cash of $1.0bn on 2026-09-30; operating cash flow positive
Press releases filed as 8-K in the last year:
Held by 3 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Amneal Pharmaceuticals Aragon Pharmaceuticals REGENXBIO CG Oncology Spur Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.